Low Load Blood Flow Restriction Training Versus Traditional Heavy Load Resistance Training in Male Athletes With Sub-acute Non-specific Low Back Pain

March 17, 2026 updated by: Mahnoor Ijaz, University of Lahore
his randomized clinical trial aims to compare the effects of low-load blood flow restriction (LL-BFR) training and traditional heavy-load resistance training (HL-RT) on male athletes with sub-acute non-specific low back pain. Participants will be randomly assigned to either the LL-BFR or HL-RT group for a specified intervention period. Both groups will perform supervised exercise sessions targeting core and lumbar stabilizing muscles. Outcomes including pain intensity, functional disability, and muscle strength will be assessed at baseline and post-intervention. The study seeks to determine whether LL-BFR can provide comparable or superior benefits to HL-RT while reducing mechanical stress on the lumbar spine.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
64

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
      • Lahore, Pakistan
        • UIPT, UOL, Lahore

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • • Male athletes (Liu et al., 2025)

    • Age 18-24 years (Liu et al., 2025)
    • Athletes like wrestlers, weightlifters and sprinters
    • Report pain and discomfort localized below the costal margin and above the inferior gluteal folds. (Adhikari et al., 2021)
    • Subacute low back pain - Pain lasting between 4 to 12 weeks. (Chou & Atlas, 2023)
    • Participants with moderate level of pain on Visual analogue scale.(Nambi et al., 2022)
    • Negative straight-leg-raising (SLR) test, which is useful for diagnosing lumbar disc herniation. (Jardim et al., 2022)
    • No dominant leg pain from radicular or cauda equina disorders. (Liu et al., 2025)
    • No history of previous lumbar or thoracolumbar spine surgery. (Jardim et al., 2022)

Exclusion Criteria:

  • Any prior lumbar or thoracolumbar spine surgery (Liu et al., 2025)
  • A history of cancer, spinal infection, rheumatologic diseases, spine fracture, red flag signs (such as significant and unexplained weight loss exceeding 10% of total body weight within the past six months, and presence of fever), psychological disorders, and previous spine surgery, radiculopathy, anatomical or congenital abnormalities. (Hernandez-Lucas et al., 2023)
  • History of peripheral arterial disease or deep vein thrombosis. (Jardim et al., 2022)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Low Load Blood Flow Restriction Training (LL-BFR)
Other: Low Load Blood Flow Restriction Training (LL-BFR)
Participants will perform low-load resistance exercises with elastic occlusion cuffs on the proximal thighs, combined with four core exercises (Glute Bridge, Wall Sit, Step-Ups, Bird-Dog). Sessions last 50 minutes, three times per week for 4 weeks. Exercise intensity starts at 20% of 1RM and progresses to 35%, with sets and repetitions designed to improve core strength, reduce pain, and enhance spinal stabilization.
Other: Traditional Heavy Load Resistance Training (HL-RT)
Participants will perform high-load resistance exercises without occlusion cuffs, using the same four core exercises. Sessions last 55 minutes, three times per week for 4 weeks. Intensity starts at 50% of 1RM and progresses to 75-80%, with sets and repetitions aimed at improving muscle strength, core stability, and reducing pain and functional disability.
Active Comparator: Traditional Heavy Load Resistance Training (HL-RT)
Other: Low Load Blood Flow Restriction Training (LL-BFR)
Participants will perform low-load resistance exercises with elastic occlusion cuffs on the proximal thighs, combined with four core exercises (Glute Bridge, Wall Sit, Step-Ups, Bird-Dog). Sessions last 50 minutes, three times per week for 4 weeks. Exercise intensity starts at 20% of 1RM and progresses to 35%, with sets and repetitions designed to improve core strength, reduce pain, and enhance spinal stabilization.
Other: Traditional Heavy Load Resistance Training (HL-RT)
Participants will perform high-load resistance exercises without occlusion cuffs, using the same four core exercises. Sessions last 55 minutes, three times per week for 4 weeks. Intensity starts at 50% of 1RM and progresses to 75-80%, with sets and repetitions aimed at improving muscle strength, core stability, and reducing pain and functional disability.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Numeric Pain Rating Scale (NPRS) for Pain Intensity in Sub-Acute Non-Specific Low Back Pain
Time Frame: Baseline and 4 weeks
Pain intensity in participants with sub-acute non-specific low back pain will be assessed using the Numeric Pain Rating Scale (NPRS), an 11-point self-reported pain scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Participants will be asked to rate their average low back pain during the past 24 hours by selecting a number from 0 to 10.
Baseline and 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Lahore

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 10, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 10, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 10, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 17, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 15, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 18, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 20, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 17, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Mahnoor Ijaz

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings